Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE)
Clinical Trials URL:
http://clinicaltrials.gov/ct2/show/...
Study Type:
Clinical Trial
Prepared on October 13, 2008
Last Updated on January 15, 2008
Study Dates: November 1995 - June 2005
Consent: Restricted Consent
Consent Restrictions: Research restricted to predictors of coronary heart disease progression
Commercial Use Restrictions:
No
NHLBI Division: DCVS
Collection Type: Open BioLINCC Study
- See bottom of this webpage for request information
Objectives
To conduct a trial to test the hypothesis that patients with stable coronary artery disease and normal or slightly reduced left ventricular function derive therapeutic benefit from the addition of ACE inhibitors to modern conventional therapy.
Background
Angiotensin-converting-enzyme (ACE) inhibitors are effective in reducing the risk of heart failure, myocardial infarction, and death from cardiovascular causes in patients with left ventricular systolic dysfunction or heart failure. ACE inhibitors have also been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure.
Subjects
The trial was a double-blind, placebo-controlled study in which 8290 patients were randomly assigned to receive either trandolapril at a target dose of 4 mg per day (4158 patients) or matching placebo (4132 patients).
Conclusions
In patients with stable coronary heart disease and preserved left ventricular function who are receiving "current standard" therapy and in whom the rate of cardiovascular events is lower than in previous trials of ACE inhibitors in patients with vascular disease, there is no evidence that the addition of an ACE inhibitor provides further benefit in terms of death from cardiovascular causes, myocardial infarction, or coronary revascularization. (NEJM 2004;351:2058-2068)